Skip to main content
Maximilian Diehn, MD, Radiation Oncology, Stanford, CA

Maximilian Diehn MD

Thoracic Cancer


Associate Professor, Radiation Oncology, Stanford University Medical Center

Join to View Full Profile
  • 875 Blake Wilbur DrDept of Radiation Oncology Mc5847Stanford, CA 94305

  • Phone+1 650-723-6171

Dr. Diehn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2005 - 2009
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2004 - 2005
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 2004

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - 2025
  • Radiation Oncology
    American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
    Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
    Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
    Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Methods and Applications of cfDNA Analysis 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • HMN 2025: How Cell-Free RNA Blood Check Identifies Early-Stage Cancers, Screens Therapy Resistance and Detects Tissue Harm
    HMN 2025: How Cell-Free RNA Blood Check Identifies Early-Stage Cancers, Screens Therapy Resistance and Detects Tissue HarmApril 27th, 2025
  • Liquid Biopsy Uses mRNA to Diagnose Cancer, Treatment Resistance, Tissue Damage
    Liquid Biopsy Uses mRNA to Diagnose Cancer, Treatment Resistance, Tissue DamageApril 23rd, 2025
  • Stanford Medicine Researchers Create RNA Blood Test to Detect Cancer and Other Indicators
    Stanford Medicine Researchers Create RNA Blood Test to Detect Cancer and Other IndicatorsApril 21st, 2025
  • Join now to see all

Grant Support

  • Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapySTANFORD UNIVERSITY2024–2029
  • Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
  • Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
  • Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
  • Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
  • Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
  • Circulating Genomic Determinants of Treatment Failure in Hodgkin LymphomaSTANFORD UNIVERSITY2021–2026
  • Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
  • Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
  • Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancerSTANFORD UNIVERSITY2020–2025
  • Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
  • Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
  • Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
  • Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancerSTANFORD UNIVERSITY2019–2024

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: